Essential Thrombocythemia - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：70頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Essential Thrombocythemia - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Essential Thrombocythemia - Pipeline Review, H1 2014’, provides an overview of the Essential Thrombocythemia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Essential Thrombocythemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Essential Thrombocythemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Essential Thrombocythemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Essential Thrombocythemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Essential Thrombocythemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Essential Thrombocythemia - Pipeline Review, H1 2014’, provides an overview of the Essential Thrombocythemia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Essential Thrombocythemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Essential Thrombocythemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Essential Thrombocythemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Essential Thrombocythemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Essential Thrombocythemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Essential Thrombocythemia Overview 7
Therapeutics Development 8
Pipeline Products for Essential Thrombocythemia - Overview 8
Pipeline Products for Essential Thrombocythemia - Comparative Analysis 9
Essential Thrombocythemia - Therapeutics under Development by Companies 10
Essential Thrombocythemia - Therapeutics under Investigation by Universities/Institutes 12
Essential Thrombocythemia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Essential Thrombocythemia - Products under Development by Companies 16
Essential Thrombocythemia - Products under Investigation by Universities/Institutes 17
Essential Thrombocythemia - Companies Involved in Therapeutics Development 18
AstraZeneca PLC 18
Eli Lilly and Company 19
Gilead Sciences, Inc. 20
Shire Plc 21
Incyte Corporation 22
Galena Biopharma, Inc. 23
Pharma Mar, S.A. 24
Essential Thrombocythemia - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
anagrelide hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ruxolitinib phosphate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
plitidepsin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
simtuzumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
gandotinib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AZD-1480 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
anagrelide hydrochloride CR - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
JAK Inhibitors - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Essential Thrombocythemia - Recent Pipeline Updates 49
Essential Thrombocythemia - Dormant Projects 57
Essential Thrombocythemia - Discontinued Products 58
Essential Thrombocythemia - Product Development Milestones 59
Featured News & Press Releases 59
Jun 16, 2013: Geron Announces Presentation Of Updated Results From Imetelstat Phase II Trial In Essential Thrombocythemia At 18th EHA Congress 59
Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance 60
Dec 10, 2012: Geron Presents Positive Results From Phase II Study Of Imetelstat In Essential Thrombocythemia At ASH Annual Meeting 61
May 31, 2011: YM BioSciences Announces Orphan Drug Designation For JAK1/JAK2 Inhibitor CYT387 In Europe 63
Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting 63
Mar 03, 2010: Geron Gives Five Presentations On Telomerase Inhibitor Imetelstat At The AACR Annual Meeting 65
May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis 67
Apr 18, 2005: IMPAX Receives Final FDA Approval for Generic Version Of Agrylin; Third Approval in 2005 68
Apr 18, 2005: Mylan Receives Approval for Anagrelide Hydrochloride Capsules 68
May 28, 2004: US-FDA grants Six months additional market exclusivity for AGRYLIN. 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70
List of Tables
Number of Products under Development for Essential Thrombocythemia, H1 2014 8
Number of Products under Development for Essential Thrombocythemia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Essential Thrombocythemia - Pipeline by AstraZeneca PLC, H1 2014 18
Essential Thrombocythemia - Pipeline by Eli Lilly and Company, H1 2014 19
Essential Thrombocythemia - Pipeline by Gilead Sciences, Inc., H1 2014 20
Essential Thrombocythemia - Pipeline by Shire Plc, H1 2014 21
Essential Thrombocythemia - Pipeline by Incyte Corporation, H1 2014 22
Essential Thrombocythemia - Pipeline by Galena Biopharma, Inc., H1 2014 23
Essential Thrombocythemia - Pipeline by Pharma Mar, S.A., H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Stage and Target, H1 2014 27
Number of Products by Stage and Mechanism of Action, H1 2014 29
Number of Products by Stage and Route of Administration, H1 2014 31
Number of Products by Stage and Molecule Type, H1 2014 33
Essential Thrombocythemia Therapeutics - Recent Pipeline Updates, H1 2014 49
Essential Thrombocythemia - Dormant Projects, H1 2014 57
Essential Thrombocythemia - Discontinued Products, H1 2014 58
List of Figures
Number of Products under Development for Essential Thrombocythemia, H1 2014 8
Number of Products under Development for Essential Thrombocythemia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 14
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Top 10 Target, H1 2014 26
Number of Products by Stage and Top 10 Target, H1 2014 27
Number of Products by Top 10 Mechanism of Action, H1 2014 28
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 29
Number of Products by Top 10 Route of Administration, H1 2014 30
Number of Products by Stage and Top 10 Route of Administration, H1 2014 31
Number of Products by Top 10 Molecule Type, H1 2014 32
Number of Products by Stage and Top 10 Molecule Type, H1 2014 33
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Essential Thrombocythemia Overview 7
Therapeutics Development 8
Pipeline Products for Essential Thrombocythemia - Overview 8
Pipeline Products for Essential Thrombocythemia - Comparative Analysis 9
Essential Thrombocythemia - Therapeutics under Development by Companies 10
Essential Thrombocythemia - Therapeutics under Investigation by Universities/Institutes 12
Essential Thrombocythemia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Essential Thrombocythemia - Products under Development by Companies 16
Essential Thrombocythemia - Products under Investigation by Universities/Institutes 17
Essential Thrombocythemia - Companies Involved in Therapeutics Development 18
AstraZeneca PLC 18
Eli Lilly and Company 19
Gilead Sciences, Inc. 20
Shire Plc 21
Incyte Corporation 22
Galena Biopharma, Inc. 23
Pharma Mar, S.A. 24
Essential Thrombocythemia - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
anagrelide hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ruxolitinib phosphate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
plitidepsin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
simtuzumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
gandotinib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AZD-1480 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
anagrelide hydrochloride CR - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
JAK Inhibitors - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Essential Thrombocythemia - Recent Pipeline Updates 49
Essential Thrombocythemia - Dormant Projects 57
Essential Thrombocythemia - Discontinued Products 58
Essential Thrombocythemia - Product Development Milestones 59
Featured News & Press Releases 59
Jun 16, 2013: Geron Announces Presentation Of Updated Results From Imetelstat Phase II Trial In Essential Thrombocythemia At 18th EHA Congress 59
Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance 60
Dec 10, 2012: Geron Presents Positive Results From Phase II Study Of Imetelstat In Essential Thrombocythemia At ASH Annual Meeting 61
May 31, 2011: YM BioSciences Announces Orphan Drug Designation For JAK1/JAK2 Inhibitor CYT387 In Europe 63
Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting 63
Mar 03, 2010: Geron Gives Five Presentations On Telomerase Inhibitor Imetelstat At The AACR Annual Meeting 65
May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis 67
Apr 18, 2005: IMPAX Receives Final FDA Approval for Generic Version Of Agrylin; Third Approval in 2005 68
Apr 18, 2005: Mylan Receives Approval for Anagrelide Hydrochloride Capsules 68
May 28, 2004: US-FDA grants Six months additional market exclusivity for AGRYLIN. 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70
List of Tables
Number of Products under Development for Essential Thrombocythemia, H1 2014 8
Number of Products under Development for Essential Thrombocythemia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Essential Thrombocythemia - Pipeline by AstraZeneca PLC, H1 2014 18
Essential Thrombocythemia - Pipeline by Eli Lilly and Company, H1 2014 19
Essential Thrombocythemia - Pipeline by Gilead Sciences, Inc., H1 2014 20
Essential Thrombocythemia - Pipeline by Shire Plc, H1 2014 21
Essential Thrombocythemia - Pipeline by Incyte Corporation, H1 2014 22
Essential Thrombocythemia - Pipeline by Galena Biopharma, Inc., H1 2014 23
Essential Thrombocythemia - Pipeline by Pharma Mar, S.A., H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Stage and Target, H1 2014 27
Number of Products by Stage and Mechanism of Action, H1 2014 29
Number of Products by Stage and Route of Administration, H1 2014 31
Number of Products by Stage and Molecule Type, H1 2014 33
Essential Thrombocythemia Therapeutics - Recent Pipeline Updates, H1 2014 49
Essential Thrombocythemia - Dormant Projects, H1 2014 57
Essential Thrombocythemia - Discontinued Products, H1 2014 58
List of Figures
Number of Products under Development for Essential Thrombocythemia, H1 2014 8
Number of Products under Development for Essential Thrombocythemia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 14
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Top 10 Target, H1 2014 26
Number of Products by Stage and Top 10 Target, H1 2014 27
Number of Products by Top 10 Mechanism of Action, H1 2014 28
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 29
Number of Products by Top 10 Route of Administration, H1 2014 30
Number of Products by Stage and Top 10 Route of Administration, H1 2014 31
Number of Products by Top 10 Molecule Type, H1 2014 32
Number of Products by Stage and Top 10 Molecule Type, H1 2014 33
